INTRODUCTION {#s1}
============

Axons in the brain and spinal cord do not regenerate after injury because of a low intrinsic capacity for growth and extrinsic inhibitory factors ([@JCS207423C17]; [@JCS207423C20]). Targeting inhibitory factors can promote recovery through sprouting and plasticity ([@JCS207423C48]; [@JCS207423C50]), but these interventions need to be combined with a strategy that promotes long-range growth to optimise functional recovery. A number of studies have therefore focused on enhancing intrinsic regenerative capacity. These studies have identified signalling pathways and genetic factors that can be targeted to promote regeneration ([@JCS207423C30]; [@JCS207423C31]; [@JCS207423C36]); however, regenerated axons often fail to reach their correct targets ([@JCS207423C41]) and the cellular mechanisms downstream of these regeneration regulators are not completely understood. Investigating the mechanisms governing regenerative ability will help to explain how single interventions can orchestrate the numerous changes required to convert a dormant fibre into a dynamic structure capable of long-range growth ([@JCS207423C7]).

Neurons in the peripheral nervous system (PNS) have a much greater capacity for regeneration, and can regenerate over long distances through the spinal cord if provided with an appropriate activated integrin ([@JCS207423C10]). Integrins are adhesion molecules that mediate PNS regeneration, but are excluded from CNS axons after development ([@JCS207423C2]; [@JCS207423C18]). They are transported into PNS axons in recycling endosomes marked by the small GTPase Rab11 (which has two forms, Rab11a and Rab11b in mammals) ([@JCS207423C15]). Rab11 governs the trafficking of many growth-promoting molecules ([@JCS207423C51]; [@JCS207423C57]), and is necessary for growth cone function during development ([@JCS207423C1]; [@JCS207423C55]). However, Rab11 is also excluded from mature CNS axons ([@JCS207423C18]; [@JCS207423C49]). We reasoned that restriction of Rab11 vesicles and their contents could be a major cause of regeneration failure, and that its reversal might be one of the mechanisms required to convert a quiescent axon into one capable of growth. Using a cell biology approach, we set out to determine how integrin and Rab11 exclusion is controlled, whether it plays a part in governing regenerative ability and how its regulation differs in PNS versus CNS neurons.

We have previously found that several influences are responsible for excluding integrins from CNS axons (cortical neurons), including the axon initial segment (AIS) and a mechanism involving dynein-dependent retrograde transport regulated by the small GTPase ARF6 ([@JCS207423C18]). An ARF6--Rab11--JIP3/4 (JIP3 is also known as MAPK8IP3, and JIP4 as SPAG9) complex is known to control the direction of recycling endosome transport ([@JCS207423C35]). We reasoned that there may be an ARF6 activator in the AIS that prevents axonal integrin transport by stimulating retrograde transport, and unites these apparently unconnected mechanisms. We aimed to identify a single molecule that could be targeted to facilitate transport and promote regeneration, and might function as a focal point to regulate signalling and transport mechanisms from the AIS. This would mean that, in the future, it might be possible to use integrins to promote guided regeneration of CNS axons through the spinal cord, as has already been achieved for sensory axons ([@JCS207423C10]).

Our hypothesis was that the exclusion of integrins and Rab11-positive recycling endosomes from adult CNS axons contributes to their inability to regenerate; that restoring the ability of CNS axons to transport growth-promoting machinery should boost their intrinsic regenerative ability. For this work, we have used a model of progressive regeneration failure in maturing cortical neurons validated in our previous research ([@JCS207423C18]; [@JCS207423C25]).

We identify the AIS-enriched ARF6 guanine-nucleotide-exchange factor (GEF) EFA6 as a key molecule controlling selective axon transport and regenerative ability in CNS neurons. ARF6 and Rab11 function as part of a complex, with ARF6 activation regulating transport direction ([@JCS207423C35]). We used live-cell imaging to determine that EFA6 regulates not only integrin transport, but also the transport of recycling endosomes marked by Rab11. Removing EFA6 allows transport throughout CNS axons, and enables them to regenerate more efficiently after *in vitro* laser axotomy. This led us to understand why sensory axons have a much higher ability to regenerate than CNS neurons. In sensory neurons there is no transport block ([@JCS207423C2]), and EFA6 is not enriched in the initial part of axons. In these neurons, EFA6 activity is counteracted by an ARF6 inactivator which is not present in CNS neurons (ACAP1) and overexpressed EFA6 inhibits regeneration. Our results demonstrate that EFA6 and ARF6 are intrinsic regulators of regenerative capacity, and that they can be targeted to restore transport and promote regeneration.

RESULTS {#s2}
=======

EFA6 localises to the AIS and activates axonal ARF6 {#s2a}
---------------------------------------------------

The ARF6 GEF EFA6 opposes axon regeneration in *C. elegans* ([@JCS207423C11]) and is strongly upregulated as CNS neurons mature and develop selective polarised transport ([@JCS207423C13]). We used immunofluorescence to examine EFA6 localisation in rat cortical neurons differentiating *in vitro*. From 7 days *in vitro* (DIV), EFA6 was enriched in the initial part of the axon, where it colocalised with the AIS marker neurofascin ([Fig. 1](#JCS207423F1){ref-type="fig"}A). It was also present at lower levels throughout the dendrites and the cell body, as previously reported ([@JCS207423C13]) ([Fig. 1](#JCS207423F1){ref-type="fig"}A,B). EFA6 is an ARF6 GEF ([@JCS207423C33]), which also regulates microtubules in *C. elegans* ([@JCS207423C11]). We therefore investigated whether EFA6 was regulating ARF protein activation and/or microtubule dynamics. To investigate EFA6 GEF activity, we visualised activated ARF protein by using the ARF-binding domain (ABD) of GGA3 fused to a GST tag in 14 DIV neurons. GGA3 is a clathrin-binding protein ([@JCS207423C23]; [@JCS207423C42]) that interacts only with the active form of ARF proteins ([@JCS207423C47]). ARF protein activation was not restricted to the AIS; instead we found a strong signal throughout axons ([Fig. 2](#JCS207423F2){ref-type="fig"}A). Importantly, this signal was not evident at 4 DIV (when integrins and Rab11 are transported into cortical axons). At this stage, when EFA6 was not enriched in the AIS, sparse vesicular structures were observed along the axons and these diminished at growth cones ([Fig. 2](#JCS207423F2){ref-type="fig"}B). Imaging at higher magnification confirmed that active ARF protein was detected uniformly along axons at the later developmental stage (14 DIV) ([Fig. 2](#JCS207423F2){ref-type="fig"}C). To determine whether EFA6 was involved in axonal ARF protein activation in differentiated neurons, we depleted EFA6 with shRNA ([Fig. S1](Fig. S1)). This led to a strong reduction in ARF protein activation throughout the axon, but did not affect the total amount of ARF6 ([Fig. 2](#JCS207423F2){ref-type="fig"}D). EFA6 preferentially activates ARF6 ([@JCS207423C33]), so our finding suggests that EFA6 functions to activate ARF6 throughout axons, despite being restricted to the AIS. We next examined whether rodent EFA6 regulates microtubule dynamics by live imaging of the microtubule end-binding protein EB3--GFP (EB3 is also known as MAPRE3), both in the AIS and throughout the axons of neurons expressing either control or EFA6 shRNA. We found that EB3--GFP was enriched in the AIS of control-transfected neurons, as previously reported ([@JCS207423C28]). Silencing EFA6 with shRNA had no effect on this distribution ([Movies 1](Movies 1) and [2](2)), suggesting that EFA6 does not affect microtubule stabilisation within the AIS ([@JCS207423C28]). As a result of the high density of EB3 in the AIS, we did not detect comets here, even after depletion of EFA6. EB3--GFP comets were detected more distally into axons, but silencing EFA6 had no effect on either the number or behaviour of comets ([Fig. S2](Fig. S2)). These data suggest that the developmental rise of EFA6 in the AIS leads to activation of ARF6 throughout mature CNS axons. However, rodent EFA6 does not regulate axonal microtubule dynamics as has been observed in *C. elegans*. This is consistent with the absence of the microtubule-binding domain in mammalian EFA6. Fig. 1.**EFA6 is enriched in the AIS.** (A) Immunolabelling of EFA6 and neurofascin in cortical neurons (E18, plus 4 to 21 DIV). EFA6 is expressed at low levels throughout the cell at an early stage (E18, 4 DIV). Expression increases with maturity, and EFA6 is enriched at the AIS from 7 DIV onwards. EFA6 is in green colour; pan-neurofascin is red (to identify the AIS). Arrows indicate the AIS. Spectrum colouring indicates the highest signal in the AIS. (B) Quantification of mean fluorescence intensity of EFA6 in the AIS, axon, initial dendrite and dendrite. *n*=45 neurons from three separate experiments. \*\*\**P*\<0.0001; n.s., not significant (ANOVA and Bonferroni\'s comparison test). All error bars are s.e.m. Fig. 2.**EFA6 activates ARF throughout mature CNS axons.** (A) Active ARF proteins (GGA3--ABD--GST, green) in proximal axons (neurofascin in blue), and distal axons (axon neurofilaments, red) at 14 DIV. The ellipse indicates the initial segment; arrows indicate a distal axon. (B) In young neurons (4 DIV), active ARF is detected in sparse tubulovesicular structures throughout developing axons, which diminish at the growth cone. (C) In differentiated neurons (14 DIV) active ARF (GGA3--ABD--GST+anti-GST) is distributed uniformly throughout axons (as indicated by immunolabelling with SMI312 for axonal neurofilaments). (D) Active ARF and total ARF6 in axons of neurons expressing either control shRNA or shRNA targeting EFA6 (red). Active ARF or ARF6 is shown in green, as indicated. Arrows indicate axons. Quantification of mean axonal ARF activity and total (mean) ARF6 in neurons expressing either control or EFA6 shRNA. *n*=61 and 64 neurons, respectively (for active ARF), *n*=50 for total ARF6 quantification. \*\*\**P*\<0.0001 (two-tailed Student\'s *t*-test). All error bars are s.e.m.

EFA6 directs integrins away from axons {#s2b}
--------------------------------------

Whereas endogenous integrins are restricted to dendrites in differentiated CNS neurons, overexpressed integrins enter proximal axons where they exhibit predominantly retrograde transport. Retrograde transport is one mechanism through which a polarised distribution can be achieved in neurons ([@JCS207423C22]; [@JCS207423C26]). The direction of axonal integrin transport is regulated by ARF6 activation state, such that elevated ARF6 activation causes retrograde transport, whereas ARF6 inactivation facilitates anterograde transport ([@JCS207423C16]; [@JCS207423C18]). Removal of the chief ARF6 activator, EFA6, should therefore facilitate anterograde integrin transport. We used live spinning disc confocal microscopy to image and analyse axonal integrin movement at three points (AIS, proximal and distal) by visualising α9-integrin--GFP (this integrin promotes spinal sensory regeneration; [@JCS207423C10]), in the presence of EFA6 shRNA or control. Anterograde transport was almost undetectable in control-transfected neurons. These exhibited predominantly retrograde and static vesicles, and there was a rapid decline in integrin levels with distance ([Fig. 3](#JCS207423F3){ref-type="fig"}A,B; [Fig. S3](Fig. S3), [Movies 3](Movies 3) and [4](4)). Depleting EFA6 initiated anterograde transport, diminished retrograde transport, and increased integrins in all segments of the axon (mean 8.3 vesicles per section for the AIS, 7.9 for the proximal section, 7.1 for the distal section). Endogenous β1 integrin (the binding partner of integrin α9) also entered axons. Measurement of the axon-to-dendrite ratio showed that depleting EFA6 led to integrins being present in axons at a similar level to in dendrites (axon-to-dendrite ratio changing from 0.24 in control-transfected neurons, to 0.95 in neurons expressing EFA6 shRNA) ([Fig. 3](#JCS207423F3){ref-type="fig"}C,D). We also quantified the mean axonal β1 integrin fluorescence intensity, which increased from 13.4 to 37.0 (arbitrary units, a.u.) ([Fig. 3](#JCS207423F3){ref-type="fig"}C,E). Removing the ARF6 GEF EFA6 therefore enables anterograde integrin transport and increases integrin levels throughout the axon. Fig. 3.**Depletion of EFA6 promotes axon transport of α9 and β1 integrins.** (A) Kymographs showing dynamics of α9 integrin--GFP in the AIS, proximal and distal axon of neurons expressing control or EFA6 shRNA. (B) Quantification of α9 integrin--GFP axon transport; *n*=12 AIS control, 19 AIS experimental, 12 proximal control, 24 proximal experimental, 23 distal control and, 24 distal experimental, total 1024 vesicles. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001 (ANOVA and Bonferroni\'s comparison test). (C) Immunolabelling of β1 integrin in neurons expressing control or EFA6 shRNA. Arrows indicate axons. (D) Quantification of axon-to-dendrite ratio for endogenous β1 integrin after EFA6 silencing; *n*=67 neurons from three experiments. \*\*\**P*\<0.0001 (Student\'s *t*-test). (E) Quantification of mean axon fluorescence intensity of endogenous β1 integrin after EFA6 silencing; *n*=67 neurons from three experiments. \*\*\**P*\<0.0001 (two-tailed Student\'s *t*-test). All error bars are s.e.m.

EFA6 directs Rab11 endosomes away from axons, but does not affect APP transport {#s2c}
-------------------------------------------------------------------------------

Axonal integrins traffic via recycling endosomes marked by Rab11. This small GTPase is necessary for growth cone function during developmental axon growth in the CNS and involved in axon regeneration ([@JCS207423C15]; [@JCS207423C38]; [@JCS207423C55]). However, it is excluded from mature CNS axons ([@JCS207423C18]; [@JCS207423C49]). Rab11 and ARF6 cooperate to control microtubule-based transport direction ([@JCS207423C35]) and axon growth ([@JCS207423C16], [@JCS207423C15]; [@JCS207423C54]). From its effects on integrin transport, we reasoned that EFA6 may be pivotal in directing Rab11 away from axons. As with integrins, some overexpressed Rab11--GFP leaks into CNS axons (detectable as vesicular punctae), although at much lower levels than is seen in dendrites. This allows for analysis of axonal vesicle dynamics ([Fig. 4](#JCS207423F4){ref-type="fig"}A). In the AIS individual vesicles could not be distinguished ([Fig. 4](#JCS207423F4){ref-type="fig"}A, AIS kymograph). Beyond the AIS, anterograde transport was minimal in control-transfected cells, with the majority of vesicles moving in a retrograde direction, moving bidirectionally or remaining immobile. Overall transport declined with distance (mean 12.3 vesicles per proximal section, 6.7 per distal section, [Fig. 4](#JCS207423F4){ref-type="fig"}B). Expressing EFA6 shRNA stimulated anterograde transport. There was also a reduction in retrograde transport in the proximal axon, an increase in bidirectional movement in the distal axon, and an increase in immobile puncta throughout the axon ([Fig. 4](#JCS207423F4){ref-type="fig"}A,B; [Fig. S3B](Fig. S3B)). These transport changes permitted endogenous Rab11 to enter axons, altering the axon-to-dendrite ratio from 0.35 to 0.94 (control versus EFA6 shRNA) ([Fig. 4](#JCS207423F4){ref-type="fig"}C,D). We also quantified the mean axonal Rab11 fluorescence intensity, which increased from 25.2 to 70.1 a.u. ([Fig. 4](#JCS207423F4){ref-type="fig"}C,E). EFA6 therefore functions to limit the axonal localisation of Rab11-positive endosomes containing integrins, and numerous other molecules. To confirm the selectivity of these effects, we also analysed the transport of amyloid precursor protein (APP), a molecule which targets to CNS axons ([@JCS207423C12]) that is not normally found in Rab11 endosomes ([@JCS207423C53]). We found no differences in APP axon transport dynamics between neurons expressing control or EFA6 shRNA ([Fig. 4](#JCS207423F4){ref-type="fig"}E,F), indicating that EFA6 depletion does not alter global axon transport. Fig. 4.**Depletion of EFA6 promotes axon transport of Rab11, and not APP.** (A) Kymographs showing dynamics of Rab11--GFP in the AIS, and proximal and distal section of the axon of neurons expressing control or EFA6 shRNA. (B) Quantification of Rab11--GFP axon transport; *n*=27 control proximal, 19 experimental proximal, 31 control distal, 38 experimental distal. \**P*\<0.05; \*\*\**P*\<0.001 (ANOVA and Bonferroni\'s comparison test). (C) Immunolabelling of Rab11 in neurons expressing either control or EFA6 shRNA. Arrows indicate axons. (D) Quantification of the axon-to-dendrite ratio for endogenous Rab11 after EFA6 silencing. *n*=71 neurons from three experiments. \*\*\**P*\<0.0001 (Student\'s *t*-test). Also see the associated [Fig. S2](Fig. S2). (E) Quantification of mean axon fluorescence intensity of endogenous β1 integrin after EFA6 silencing. *n*=71 neurons from three experiments. \*\*\**P*\<0.0001 (two-tailed Student\'s *t*-test). (F) Kymographs showing dynamics of APP--GFP in the proximal and distal axons of neurons expressing either control shRNA or shRNA targeting EFA6. (G) Quantification of APP--GFP vesicle movements in the proximal and distal axon *n*=12, 13, 17 and 17. No statistical difference was found between neurons expressing control or EFA6 shRNA using ANOVA and Bonferroni\'s comparison test. All error bars are s.e.m.

EFA6 depletion enhances regeneration of CNS axons {#s2d}
-------------------------------------------------

Rab11, integrins and reduced ARF6 activity are all beneficial for axon growth ([@JCS207423C10]; [@JCS207423C18]; [@JCS207423C55]). We therefore asked whether silencing EFA6 would intrinsically enhance regeneration. *In vitro* single-cell axotomy enables detailed study of intrinsic regenerative capacity, allowing morphological evaluation of the regenerative response after injury ([@JCS207423C21]). We developed an *in vitro* laser axotomy protocol for analysing the regeneration of individually axotomised cortical neurons ([@JCS207423C25]). Embryonic day (E)18 rat cortical neurons were cultured on glass imaging dishes, transfected at 10 DIV, and used for experiments at 14--17DIV. We used this system to study the effects of EFA6 depletion on regeneration of cortical neurons after laser axotomy ([Fig. 5](#JCS207423F5){ref-type="fig"}A; [Fig. S4](Fig. S4)). When regeneration was successful, we recorded growth cone size, the time taken to regenerate and the distance grown after regeneration (within the experimental time frame). We recorded whether axons formed stumps or motile end bulbs after injury when regeneration failed ([Fig. 5](#JCS207423F5){ref-type="fig"}B,C). By 14 DIV, integrins and Rab11 are mostly excluded from axons, and their ability to regenerate is limited ([@JCS207423C25]). Neurons expressing EFA6 shRNA showed a substantial increase in regeneration with 57.6% of neurons regenerating their axons within 14 h, compared to 27.4% of neurons expressing control shRNA ([Fig. 5](#JCS207423F5){ref-type="fig"}D--F; [Movies 5](Movies 5) and [6](6)). They also developed larger growth cones, extended their axons over greater distances and initiated regeneration more rapidly than cells expressing control shRNA ([Fig. 5](#JCS207423F5){ref-type="fig"}D,E,H--J). EFA6 shRNA-treated neurons tended to form motile bulbs when they failed to regenerate (84.8%), whereas control-transfected cells tended to form immobile stumps (55%) ([Fig. 5](#JCS207423F5){ref-type="fig"}B--E,G). Depleting EFA6 therefore raises the regenerative capacity of differentiated cortical neurons. Fig. 5.**Depleting EFA6 promotes axon regeneration in CNS neurons.** (A) Example of a neuron used for CNS axotomy experiments, indicating the site chosen for laser ablation (typically \>1000 µm distal, on an unbranched section of axon). The fluorescent signal is RFP expressed with control shRNA from a single plasmid. (B) Example of regeneration failure, and formation of a stump. (C) Example of post-axotomy end bulb formed after axotomy. (D) Neuron expressing control shRNA, showing axotomy followed by regeneration. Note the small growth cone (typically \<20 µm^2^ and regeneration of \<100 µm in 14 h). (E) Neuron expressing EFA6 shRNA, showing axotomy followed by regeneration \>100 µm in 14 h, with growth cones typically \>40 µm^2^. (F--J) Quantification of regenerative response of cut axons of neurons expressing either control or EFA6 shRNA. (F) Percentage of axons regenerating within a 14 h period. \*\*\**P*\<0.001 (Fisher\'s exact test). *n*=59 (control shRNA) and 63 neurons (EFA6 shRNA). (G) Percentage of failed axons with a bulb versus with a stump. \*\**P*\<0.01 (Fisher\'s exact test). (H) Distance grown after regeneration. \**P*\<0.05 (two-tailed *t*-test). *n*=17 (control shRNA) and 34 (EFA6 shRNA). (I) Area of regenerated growth cones. \*\*\**P*\<0.0001 (two-tailed *t*-test). (J) Time taken to establish a growth cone and regenerate \>50 µm. n.s., not significant (two-tailed *t*-test). All error bars are s.e.m.

ARF6 is an intrinsic regulator of regenerative capacity {#s2e}
-------------------------------------------------------

As EFA6 contributes to the low regenerative capacity of CNS neurons, we reasoned that neurons that can regenerate their axons should either have less axonal EFA6 or a means of counteracting its effects. In the PNS, adult dorsal root ganglion (DRG) neurons have regenerative axons that permit integrin and Rab11 transport ([@JCS207423C2]; [@JCS207423C19]). When we examined EFA6 in adult DRG neurons, we found remarkably high levels in the cell body and lower levels throughout axons ([Fig. 6](#JCS207423F6){ref-type="fig"}A). We speculated that this may be counteracted by an ARF6 inactivator and investigated ACAP1, a known regulator of integrin trafficking that we previously used to manipulate integrin transport in DRG axons ([@JCS207423C16]; [@JCS207423C29]). ACAP1 was present in adult DRG neurons, throughout axon shafts and at growth cones, but was absent from cortical neurons ([Fig. 6](#JCS207423F6){ref-type="fig"}A). This led us to compare ARF protein activation in DRG and differentiated cortical neurons. We found that ARF protein activation was evident in DRG axons, but at a lower level than in cortical axons ([Fig. 6](#JCS207423F6){ref-type="fig"}B). This suggests that PNS axons may be better regenerators due to expression of an ARF6 inactivator. A prediction of this hypothesis is that elevating ARF6 activation in DRG axons would inhibit regeneration. We used laser axotomy to injure the axons of adult DRG neurons *in vitro*. We examined regeneration in the presence of overexpressed GFP, EFA6--GFP or EFA6 E242K--GFP (incompetent to activate ARF6) ([Fig. 7](#JCS207423F7){ref-type="fig"}). Control DRG axons regenerate rapidly, so that by 2 h after injury 68.6% of GFP-expressing axons had developed new growth cones ([Fig. 7](#JCS207423F7){ref-type="fig"}A,C,E; [Movie 7](Movie 7)). Overexpression of EFA6 led to a dramatic reduction in regenerative capacity, with only 19.2% of axons regenerating growth cones ([Fig. 7](#JCS207423F7){ref-type="fig"}B,D,E; [Movie 8](Movie 8)). This effect was primarily due to EFA6 GEF activity, as expression of EFA6 E242K did not have the same effect, allowing 50.5% of axons to regenerate ([Fig. 7](#JCS207423F7){ref-type="fig"}E; [Fig. S5](Fig. S5)). This suggests that EFA6 opposes regeneration principally by virtue of its GEF activity towards ARF6. The data demonstrate that ARF6 activation state plays a central role in regulating the regenerative capacity of DRG neurons. Taken together with our findings in differentiated cortical neurons, our data suggest that the activation state of ARF6 is an intrinsic regulator of axon regeneration, responsible for the exclusion of Rab11 vesicles and their contents (integrins and other molecules) from CNS axons. Fig. 6.**ARF6 is regulated differently in CNS versus PNS neurons.** (A) Cortical neurons and adult DRG neurons immunolabelled for EFA6 (upper panels) or ACAP1 (lower panels). Both neuronal types were labelled and imaged identically to allow comparison of the fluorescence signal. Images represent two independent immunolabelling experiments. (B) Axons of DRG and cortical neurons (10 DIV) labelled with GGA3--ABD--GST to detect active ARF protein; spectrum colouring of the highlighted section indicates the highest signals. The asterisk and red colour in the CNS panel indicate neurofascin labelling of the AIS to identify the axon. Graph shows quantification of mean±s.e.m. ARF protein activation in the two axon types. *n*=58 (DRG) and 60 (cortical). \*\*\**P*\<0.001 (two-tailed *t*-test). Fig. 7.**EFA6 inhibits regeneration of adult DRG axons through its ARF6-activating region.** (A) Cut DRG axon expressing GFP. (B) Cut DRG axon expressing EFA6--GFP. (C) Axon from panel A showing regeneration. (D) Axon from panel B showing failure to regenerate. (E) Quantification of axon regeneration of DRG neurons expressing either GFP (*n*=48), EFA6--GFP (*n*=44) or EFA6 E242K (EFA6 lacking the ability to activate ARF6) (*n*=31). \**P*\<0.05; \*\*\**P*\<0.0001; ns, not significant (Fisher\'s exact test). All error bars are s.e.m.

DISCUSSION {#s3}
==========

Our data demonstrate that the exclusion of integrins and recycling endosomes from mature CNS axons plays an important role in limiting regenerative potential. We show that EFA6 is developmentally upregulated and enriched in the AIS at a time when integrin transport becomes predominantly retrograde ([@JCS207423C18]), and neurons lose their ability to regenerate. From its site in the initial part of the axon, EFA6 functions to activate ARF6 throughout mature axons, leading to retrograde removal of integrins and Rab11 endosomes. Removing EFA6 restores transport and facilitates regeneration. These phenomena are specific to CNS neurons, as EFA6 is not enriched in the initial part of regenerative PNS axons (of sensory DRG neurons). Sensory neurons regulate axonal ARF6 differently, by expressing the ARF GAP ACAP1, which is absent from cortical neurons. Overexpressing EFA6 opposes regeneration in these neurons, principally by virtue of its GEF domain. Our findings start to explain, at a cellular level, why PNS neurons have a better capacity for regeneration than their CNS counterparts. The results implicate ARF6 as an intrinsic regulator of regenerative potential, and identify EFA6 as a novel target for promoting CNS axon regeneration.

EFA6 activates axonal ARF to control selective polarised transport {#s3a}
------------------------------------------------------------------

We have found that EFA6 activates ARF6 throughout the axon despite being enriched in the AIS. How does EFA6 achieve ARF protein activation over long distances? This may involve a complex interaction with an additional ARF regulator, ARNO (also known as CYTH2). We have previously shown that ARNO localises throughout the axon, and that GEF-dead ARNO facilitates integrin transport and axon growth ([@JCS207423C18]). EFA6 is known to control a negative-positive feedback circuit between EFA6, ARF6 and ARNO. EFA6 is necessary to establish initial ARF activation, which is consequently maintained by ARNO ([@JCS207423C39]). In axons, the ARF activation event may be spatially regulated, with initial activation occurring within the AIS, and subsequent activation maintained throughout the axon by ARNO.

The AIS is primarily responsible for initiation of the action potential, but is also involved in the polarised delivery of membrane proteins, ensuring the correct distribution of axonal and dendritic machinery as neurons mature ([@JCS207423C5]; [@JCS207423C45]). The molecular mechanisms through which this is achieved are not completely understood, but are reported to involve the actin and microtubule cytoskeleton ([@JCS207423C3]; [@JCS207423C8]), and dynein-dependent retrograde transport ([@JCS207423C26]). We have previously found that integrins are removed from axons by dynein-dependent retrograde transport, and that lowering ARF activation reduces retrograde removal of integrins and allows modest anterograde transport. We also found that removing the AIS by silencing its central organiser, ankyrin G, also permits some anterograde transport, but we did not understand how these phenomena might be linked. Here, we establish a mechanism for the removal of both integrins and Rab11 endosomes, controlled by EFA6 from a location in the AIS. EFA6 may be localised here by virtue of its pleckstrin homology domain, which has a high degree of homology with that of the AIS component βIV spectrin ([@JCS207423C14]), but further work is necessary to investigate this. Our current data suggest a novel model for selective distribution. The selectivity comes from the involvement of the small GTPases ARF6 and Rab11, and likely involves the adaptor molecules JIP3 and JIP4. ARF6 forms a complex with Rab11, and the adaptor molecules JIP3 and JIP4; the activation state of ARF6 determines whether this complex associates with dynein or kinesin, and therefore its direction of transport ([@JCS207423C35]). We speculate that for the axonal transport of a molecule to be affected by ARF6, it needs to traffic through a Rab11- and ARF6-containing compartment, and also interact with JIP3 and JIP4. The ARF-dependent control of entry to a specific cellular compartment is not without precedent. A similar mechanism regulates the entry of rhodopsin into primary cilia. In this case, a specific ARF inactivator (ASAP1) is required to permit ARF4- and Rab11-dependent transport ([@JCS207423C56]).

Rab11, ARF6 and axon regeneration {#s3b}
---------------------------------

Much is known about the mechanisms required for growth cone formation and subsequent axon growth, but it is not understood why these mechanisms are not recapitulated after injury in the brain or spinal cord ([@JCS207423C7]). Our study demonstrates that the supply of growth-promoting material in recycling endosomes is an important factor governing regenerative potential. An axon cannot rebuild a functional growth cone without the appropriate materials. It is well established that integrins are important for axon growth during development as well as for regeneration after injury in the PNS ([@JCS207423C19]; [@JCS207423C37]), and it would appear that the same can be said for Rab11-positive recycling endosomes. These are necessary for growth cone function in CNS neurons during development ([@JCS207423C1]; [@JCS207423C55]), and now appear to participate in regeneration of CNS neurons axotomised *in vitro*. Some of the functions of Rab11 during axon growth may be due to the supply of integrins; however, other growth-promoting molecules also traffic via Rab11, including neurotrophin receptors ([@JCS207423C4]; [@JCS207423C27]), and the pro-regenerative flotillin/reggie proteins ([@JCS207423C6]).

Our data imply a central role for ARF6 and EFA6 in determining the intrinsic regenerative ability of neurons. As CNS neurons mature, EFA6 is enriched in the initial part of the axon, leading to axonal ARF activation and retrograde removal of molecules necessary for growth. Conversely, adult PNS neurons regenerate better, have low levels of EFA6 in their axons and express an ARF6 inactivator, which is not found in cortical neurons (ACAP1), and permit Rab11 and integrin transport ([@JCS207423C15]). Overexpressing EFA6 in PNS neurons leads to a reduction in regenerative capacity \[and increased retrograde transport, ([@JCS207423C16])\], while decreasing EFA6 in cortical neurons restores regeneration. These combined results suggest that ARF6 functions as an intrinsic regulator of regenerative capacity, governed by its activation state. This novel finding is in keeping with a known intrinsic regulator of regenerative potential, the tumour suppressor PTEN. Deleting PTEN enhances regeneration in the CNS, partly through the PI3K--AKT--mTOR pathway ([@JCS207423C40]). PTEN and phosphoinositide 3-kinase (PI3K) counteract each other to regulate the amounts of phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-trisphosphate (PIP3). The majority of ARF6 GEFs and GAPs are regulated downstream of PIP2 or PIP3 ([@JCS207423C44]), and the activity of EFA6 is strongly elevated in the presence of PIP2 ([@JCS207423C34]). It is therefore possible that deletion of PTEN could result in less PIP2 and lowered EFA6 activity. We hypothesise that the expression profile of axonal ARF regulators and the phosphoinositide environment are crucial factors that control the axonal entry of regenerative machinery and its subsequent insertion onto the surface membrane. These are crucial factors that determine whether a damaged axon can reconstruct a functional growth cone to drive guided axon regeneration after injury.

MATERIALS AND METHODS {#s4}
=====================

Neuron cultures and transfection {#s4a}
--------------------------------

Primary cortical neuron cultures were prepared from embryonic day 18 (E18) Sprague Dawley rats. Neurons were dissociated with papain (Worthington) for 8 min at 37°C, washed with HBSS and cultured in NeuralQ^®^ Basal Medium (AMSBio) supplemented with GS21 (AMSBio), and glutamax (Thermo). Cells were plated on glass-bottom dishes (Greiner) coated with poly-D-lysine. Culture dishes were incubated in humidified chambers to prevent evaporation of culture medium, allowing long-term culture \[up to 28 days *in vitro* (DIV)\]. DRG neuronal cultures were obtained from adult male Sprague Dawley rats. DRGs were incubated with 0.1% collagenase in Dulbecco\'s modified Eagle\'s medium (DMEM) for 90 min at 37°C followed by 10 min in trypsin at 37°C. DRGs were dissociated by trituration in a blunted glass pipette. Dissociated cells were then centrifuged through a layer of 15% bovine serum albumin (BSA), washed in DMEM, and cultured on 1 µg/ml laminin on poly-D-lysine-coated glass-bottom dishes (Greiner) in DMEM supplemented with 10% fetal calf serum (Thermo), 1% penicillin-streptomycin and 50 ng/ml nerve growth factor (NGF). Cortical neurons were transfected by oscillating nano-magnetic transfection (magnefect nano system, nanoTherics, Stoke-On-Trent, UK) as previously described ([@JCS207423C18]). For EFA6 silencing, cells were transfected at 10 DIV, and experiments (imaging or axotomy) were performed between 14 and 17 DIV. Transfections of dissociated adult DRG neurons were performed *in situ* at 1 DIV as previously described ([@JCS207423C16]) using a Cellaxess in-dish electroporator (Cellectricon).

DNA and shRNA constructs {#s4b}
------------------------

Integrin α9 EGFP-N3 was obtained from Addgene (Addgene plasmid \#13600), deposited by Prof. Dean Sheppard (University of California, San Francisco, CA), as previously characterised ([@JCS207423C16], [@JCS207423C15]; [@JCS207423C18]). cDNA encoding human Rab11a was amplified by PCR, introducing HindIII and BamHI restriction sites, and cloned into EGFP-C2 ([@JCS207423C15]). APP--GFP was a gift from Prof. Michael Coleman (Centre for Brain Repair, Cambridge University, UK) ([@JCS207423C24]). EB3--GFP was a gift from Prof. Casper Hoogenraad (Utrecht University, The Netherlands) ([@JCS207423C52]). The human EFA6 open reading frame (ORF) in pFLAG-CMV6-EFA6 ([@JCS207423C9]) was a gift from Dr. Julie Donaldson (Bethesda, MD). Human EFA6 cDNA was obtained by PCR amplification using pFLAG-CMV6-EFA6 as a template and was digested with EcoRI and SalI and cloned into the same sites of pEGFP-C1 (Clontech) to obtain pEGFPC1-EFA6 ([@JCS207423C16]). Rat EFA6 (NM_134370) in pcDNA3.1-C-(k)DYK (FLAG tag) was obtained from Genscript. EFA6 E242K--GFP ([@JCS207423C32]) was a gift from Frederic Luton (Valbonne, France). EFA6 silencing was achieved using shRNA targeting EFA6 in pRFP-C-RS (PSD gene NM_134370, targeting sequence 5′-CAGTCCTGGATTACTCGCATCAATGTGGT-3′) (Origene). Non-effective 29-mer scrambled shRNA cassette in pRFP-C-RS vector (Origene) was used as a control.

Antibodies {#s4c}
----------

Guinea pig polyclonal EFA6A (1626; 1:400) antibody was a gift from Prof. Eunjoon Kim (Daejeon, South Korea) and was previously characterised ([@JCS207423C13]) and used in independent studies ([@JCS207423C43]; [@JCS207423C46]). Other primary antibodies were: mouse anti-neurofascin clone A12/18, NeuroMab (RRID:AB_10671311), 1:200; rabbit anti-Rab11 71-5300, Thermo, 1:50; rabbit anti-ARF6 ab77581, Abcam, 1:100; rabbit anti-GST ab19256, Abcam, 1:400; mouse anti-FLAG ab18230, Abcam, 1:750; mouse anti-β-actin ab8226, Abcam, 1:1000; rabbit anti-tRFP ab233, Evrogen, 1:1000; anti-integrin ß1 clone EP1041Y, 04-1109, Millipore, 1:100; and anti-pan-axonal neurofilaments mouse monoclocal SMI312, ab24574, Abcam, 1:800. ACAP1 was detected with goat anti-centaurin β1 (ab15903, Abcam) at 1:50. Secondary antibodies were Alexa Fluor conjugates from Thermo used at 1:1000. Secondary antibodies for western blotting were horseradish peroxidase (HRP) conjugates from GE Life Sciences used at 1:10,000.

Microscopy {#s4d}
----------

Laser-scanning confocal microscopy was performed using a Leica DMI4000B microscope, with laser scanning and detection achieved by a Leica TCS SPE confocal system controlled with Leica LAS AF software. Fluorescence and wide-field microscopy was performed using a Leica DM6000B with a Leica DFC350 FX CCD camera and a Leica AF7000 with a Hamamatsu EM CCD C9100 camera and Leica LAS AF software. Leica AF7000 was also used for imaging of axon and growth cone regeneration after axotomy. Live confocal imaging was performed with an Olympus IX70 microscope using a Hamamatsu ORCA-ER CCD camera and a PerkinElmer UltraVIEW scanner for spinning disc confocal microscopy, controlled with MetaMorph software.

Analysis of EFA6 distribution in axons and dendrites {#s4e}
----------------------------------------------------

E18 cortical neurons were fixed at DIV 3, 7, 14 or 21 and EFA6 was detected using the antibody described above. The axon initial segment was located using anti-pan-neurofascin. All cultures were fixed and labelled using identical conditions. EFA6 fluorescence intensity was measured in the AIS and at a region \>50 µm beyond the AIS, and then at similar regions in two dendrites to give a mean dendrite figure. Images were acquired by confocal laser-scanning microscopy using a Leica TCS SPE confocal microscope. Identical settings were used for the acquisition of each image using Leica LAS AF software. *Z*-stacks were acquired for each image, spanning the entire depth of each neuron. GraphPad Prism was used for statistical analysis of data using ANOVA followed by Bonferroni\'s post-hoc analysis, as indicated in the figure legends.

Axonal ARF protein activation assay {#s4f}
-----------------------------------

Active ARF protein was detected using a peptide derived from the active ARF-binding domain (ABD) of GGA3 fused to a GST tag (GGA3--ABD--GST, Thermo). Neurons were fixed for 15 min in 3% formaldehyde (TAAB) in PBS, permeabilised with 0.1% Triton X-100 for 2 min and incubated with 20 µg/ml GGA3--ABD--GST in TBS and 1 mM EDTA overnight at 4°C. The GST tag was then detected using rabbit anti-GST antibody (ab19256, Abcam, 1:400) and standard immunofluorescence. Control and EFA6 shRNA-treated cultures were fixed and labelled in parallel, using identical conditions. Axons were analysed at 200--1000 µm distal to the cell body. Images of axons were acquired by confocal laser-scanning microscopy using a Leica TCS SPE confocal microscope. Initial observations were made and detection settings were adjusted so that the pixel intensities of acquired images were below saturation. Settings were then stored and were applied for the identical acquisition of each image using Leica LAS AF software. *Z*-stacks were acquired for each image, spanning the entire depth of each axon. Maximum projection images were created, and used for analysis. Lines were then traced along sections of axons to define the region of interest, and mean pixel intensities per axon section were quantified using the Leica LAS AF software. The acquired images were corrected for background by subtracting an identical region of interest adjacent to the axon being analysed. The same technique was then used for measuring total levels of ARF6 in axons, after ARF6 immunolabelling. GraphPad Prism was used for statistical analysis of data with a Student\'s *t*-test, as indicated in the figure legends.

EFA6 shRNA validation {#s4g}
---------------------

The efficacy of shRNA targeting EFA6 (target sequence 5′-CAGTCCTGGATTACTCGCATCAATGTGGT-3′) was confirmed by immunofluorescence and western blotting. E18 cortical neurons were transfected with shRNA targeting EFA6 or non-effective scramble control shRNA at 10 DIV, fixed at 14 DIV and immunolabelled for EFA6. To confirm the silencing efficiency and target validity, we used an overexpression silencing and rescue approach similar to that described previously ([@JCS207423C13]), using human EFA6 to rescue knockdown as there are base pair differences in the equivalent human sequence (cagtcctggat[C]{.ul}actcgcatcaatgt[A]{.ul}gt) compared to the rat. Preliminary experiments found that shRNA targeting rat EFA6 had no effect on human EFA6 expression levels in PC12 cells stably expressing human EFA6. We did not use this to rescue silencing in primary neurons because we found that overexpressed EFA6 localised erroneously throughout the axon. To confirm silencing by western blotting, PC12 cells were transfected with either rat EFA6--FLAG or rat EFA6--FLAG plus human EFA6--FLAG (as an shRNA-resistant rescue plasmid) together with control or EFA6 shRNA, and lysates were used for western blotting (human and rat EFA6 run at the same size on western blots; [@JCS207423C13]). Expression levels of EFA6 were determined by immunoblotting with anti-FLAG antibody. RFP and actin were probed for normalisation.

Analysis of microtubule dynamics using EB3--GFP {#s4h}
-----------------------------------------------

Cortical neurons were transfected at 10 DIV with EB3--GFP, and imaged at 13--15 DIV using spinning disc confocal microscopy. Images were acquired of cell bodies and initial sections of axons, and subsequently of regions of axons more distal into the axon (200--400 µm). Images were acquired every second for 3 min. Kymographs were generated using MetaMorph software, and used to quantify the dynamics of EB3 comets. Velocity, duration, length and number of comets were measured per axon section. ANOVA analysis confirmed there was no variation in the length of axon sections analysed. GraphPad Prism was used for statistical analysis of data through ANOVA and Bonferroni\'s post-hoc analysis.

Live imaging of α9 integrin, Rab11 and APP for axon transport analysis {#s4i}
----------------------------------------------------------------------

Cortical neurons were transfected at 10 DIV with α9 integrin--GFP, Rab11--GFP or APP--GFP together with either control or EFA6 shRNA and imaged at 14--15 DIV using spinning disc confocal microscopy. For α9 integrin--GFP and Rab11--GFP, sections of axons were imaged at the AIS, at a region in the proximal part of the axon (100--300 µm from the cell body) and a region in the distal part of the axon (\>600 µm from the cell body). APP--GFP-expressing axons were imaged at a region in the proximal part of the axon (100--300 µm from the cell body) and a region in the distal part of the axon (\>600 µm from the cell body). Vesicles were tracked for their visible lifetime, and analysed by kymography to classify the proportion of vesicles classed as anterograde, retrograde, bidirectional or immobile per axon section. This was determined as described previously ([@JCS207423C16]; [@JCS207423C18]): vesicles with a total movement less than 2 µm during their visible lifetimes were classed as immobile. Vesicles moving in both directions but with net movement of less than 2 µm (during their visible lifetimes) were classed as bidirectional, even though the total movement may have been larger. Vesicles with net movements greater than 5 µm in either direction by the end of their visible lifetimes were classed as anterograde or retrograde accordingly. ANOVA analysis confirmed there was no difference in the length of axon sections analysed (mean section lengths varied from 55 µm to 60 µm, s.e.m. 2.2--3.8). GraphPad Prism was used for statistical analysis of data through ANOVA and Bonferroni\'s post-hoc analysis.

Measurement of axon-to-dendrite ratio for β1 integrin and Rab11 {#s4j}
---------------------------------------------------------------

Cortical neurons were transfected at 10 DIV with either control or EFA6 shRNA and fixed at 14 DIV. These were immunolabelled for either β1 integrin or Rab11. Control- and EFA6 shRNA-treated cultures were fixed and labelled in parallel, using identical conditions. Images were acquired by confocal laser-scanning microscopy using a Leica TCS SPE confocal microscope, using identical settings for each image (determined separately for either β1 integrin or Rab11). Images were acquired at 40× to include the cell body, dendrites and a section of axon in each image. Leica LAS AF software was used to measure the mean fluorescence in the axon, and in two dendrites (to give a mean dendrite measurement). A region next to each neurite was used to subtract background fluorescence. The axon-to-dendrite ratio was determined as the mean dendrite fluorescence intensity divided by the axon intensity. GraphPad Prism was used for statistical analysis of data using a Student\'s *t*-test.

Axonal identification {#s4k}
---------------------

Axons and/or axon initial segments were identified either by immunolabelling of cultures with fluorescently conjugated anti-pan-neurofascin ([@JCS207423C18]) or by morphology (axons of transfected cells were clearly distinguishable from dendrites due to their length and lack of spines at more mature stages). For live labelling of neurofascin, neurons were live labelled with an Alexa-Fluor-conjugated antibody (488, 594 or 350 nm) for 45 min at 37°C. For antibody conjugation, the Tris-containing buffer of anti-neurofascin was first exchanged into 0.05 M borate buffer by dialysis using a D-tube dialyser (Novagen) and the antibody was then fluorescently labelled using a DyLight antibody labelling kit (Thermo).

Laser axotomy of cultured neurons {#s4l}
---------------------------------

Axons were severed *in vitro* using a 355 nm DPSL laser (Rapp OptoElectronic, Hamburg, Germany) connected to a Leica DMI6000B microscope. Cortical neurons were axotomised at 14--17 DIV at distances of 800--200 µm distal to the cell body on a section of axon free from branches. In this way, axons were cut at a substantial distance from the cell body, but not close to the end of the axon. Only highly polarised neurons (with many dendrites and a single axon) were chosen. A single axon cut was made per neuron. Images after axotomy were acquired every 30 min for 14 h. The response to axotomy was recorded as regeneration or fail. Regeneration was classed as the development of a new growth cone followed by axon extension for a minimum of 50 µm. Fail was then classed as either bulb or stump phenotype. Regenerated axons were analysed for the time taken to regeneration, growth cone area and length of axon growth in the 14 h following axotomy. Data regarding the regeneration percentage of cortical axons was analysed by Fisher\'s exact test. GraphPad Prism was used for statistical analysis of the remaining data. Adult DRG neurons were axotomised as described above, except that the location for axotomy was chosen as directly before a growth cone, so as to determine the proportion of axons that would regenerate a growth cone rapidly after injury. Data were analysed using Fisher\'s exact test.

Statistical analysis {#s4m}
--------------------

Statistical analysis was performed throughout using Graphpad Prism. Fisher\'s exact test was calculated using Graphpad online (<https://www.graphpad.com/quickcalcs/contingency1.cfm>). Data were analysed by ANOVA with post hoc analysis, Student\'s *t*-test and Fisher\'s exact test. Sample sizes were based on previously published data using similar techniques. For analysis of EFA6 distribution in axons and dendrites, the axon and two dendrites from 15 neurons were analysed, from three separate sets of primary cultures (a total of 45 neurons). Statistical analysis was performed using ANOVA followed by Tukey\'s multiple comparison test as indicated in the figure legends. For quantification of axonal ARF activity in cortical neurons, 61 experimental versus 64 control were analysed, from three separate experiments. For total axonal ARF6 quantification, 50 axons were analysed from three experiments. For cortical versus DRG axon ARF quantification, *n*=58 (DRG) versus 60 (cortical), from three separate experiments. Data were analysed by Student\'s *t*-test. For analysis of EB3--GFP comets, 30 experimental versus 40 control axon sections were imaged and analysed. Data were analysed by Student\'s *t*-test. Quantification of α9 integrin-GFP axon transport was performed in *n*=12--24 neurons per condition, from more than three experiments, analysed using ANOVA and Bonferroni\'s comparison test. Quantification of β1 integrin axon-dendrite ratio was performed in *n*=72 neurons in total from three experiments, analysed by Student\'s *t*-test. Quantification of Rab11--GFP axon transport was performed in *n*=19--27 neurons per condition from more than three experiments. Quantification of axon-to-dendrite ratio for Rab11 was performed in *n*=53 control versus 55 experimental neurons from three experiments, analysed by Student\'s *t*-test. Cortical neuron axon regeneration analysis was performed in *n*=59 experimental versus 63 control neurons from more than three experiments, the percentage regenerating was compared by Fisher\'s exact test. The percentage of failed axons bulb versus stumps, was compared by Fisher\'s exact test. The distance grown after regeneration, area of regenerated growth cones and time taken to establish a growth cone, were each compared by Student\'s *t*-test. Quantification of axon regeneration of DRG neurons was performed in *n*=48 expressing GFP, *n*=44 expressing EFA6-GFP or *n*=31 expressing EFA6 E242K. Data were analysed by Fisher\'s exact test.
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